» Authors » Pierre-Simon Rohrlich

Pierre-Simon Rohrlich

Explore the profile of Pierre-Simon Rohrlich including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 911
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Dericquebourg A, Jourdy Y, Fretigny M, Lienhart A, Claeyssens S, Ternisien C, et al.
Haemophilia . 2020 Aug; 26(5):847-854. PMID: 32812322
Introduction: With current molecular diagnosis, about 1 to 5% of haemophilia A (HA) patients remain genetically unresolved. In these cases, deep intronic variation or structural variation disrupting the F8 gene...
12.
Olivier-Gougenheim L, Arfeuille C, Suciu S, Sirvent N, Plat G, Ferster A, et al.
Hematol Oncol . 2020 Aug; 38(5):763-772. PMID: 32809224
Over the years, the prognosis of adolescents treated for acute lymphoblastic leukemia (ALL) has improved. However, this age group still represents a challenge with an overall survival (OS) of 60%...
13.
Lhomme F, Peyrard T, Babinet J, Abou-Chahla W, Durieu I, Moshous D, et al.
J Clin Immunol . 2020 Jun; 40(5):752-762. PMID: 32562208
Background: X-linked chronic granulomatous disease (CGD) is a primary immunodeficiency caused by mutations in the CYBB gene (located on Xp21.1). Patients with large deletions on chromosome Xp21.1 can present with...
14.
Baron F, Labopin M, Ruggeri A, Sierra J, Robinson S, Labussiere-Wallet H, et al.
Am J Hematol . 2020 May; 95(9):1057-1065. PMID: 32449964
The impact of measurable residual disease (MRD) on cord blood transplantation (CBT) outcomes has remained debated. To address this issue, we assessed the impact of measurable MRD at CBT on...
15.
Baruchel A, Bertrand Y, Boissel N, Brethon B, Ducassou S, Gandemer V, et al.
Bull Cancer . 2020 May; 107(6):629-632. PMID: 32387061
Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia...
16.
Garnache-Ottou F, Vidal C, Biichle S, Renosi F, Poret E, Pagadoy M, et al.
Blood Adv . 2019 Dec; 3(24):4238-4251. PMID: 31869411
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a...
17.
Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, de Vergnes N, et al.
J Clin Immunol . 2019 Aug; 39(7):702-712. PMID: 31401750
Purpose: Patients with primary immunodeficiency (PID) are at risk of serious complications. However, data on the incidence and causes of emergency hospital admissions are scarce. The primary objective of the...
18.
Xhaard A, Roque-Afonso A, Mallet V, Ribaud P, Nguyen-Quoc S, Rohrlich P, et al.
Viruses . 2019 Jul; 11(7). PMID: 31284515
Usually self-limited, hepatitis E virus (HEV) infection may evolve to chronicity and cirrhosis in immunosuppressed patients. HEV infection has been described in solid-organ transplantation and hematology patients, but for allogeneic...
19.
Prata P, Resche-Rigon M, Blaise D, Socie G, Rohrlich P, Milpied N, et al.
Biol Blood Marrow Transplant . 2019 May; 25(9):1798-1802. PMID: 31129355
Prognosis of patients with graft failure is dismal, and retransplantation is the sole option for long-term survival. To address the interest of haploidentical transplantation as a salvage option in this...
20.
Gagelmann N, Eikema D, de Wreede L, Koster L, Wolschke C, Arnold R, et al.
Biol Blood Marrow Transplant . 2019 Apr; 25(6):e204-e208. PMID: 30930192
We aimed to validate the MYelofibrosis SECondary to PV and ET prognostic model (MYSEC-PM) in 159 patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET) from the...